SNCA and Parkinson disease: There is no perfect model that represents all features of PD, but the model selected for a specific drug trial should obviously harbor the pathomechanism which is targeted (e.g., aggregation of alpha-synuclein), and provide a set of related pathological and behavioral readouts to measure exposure response of drug efficacy [19].